Gram-positive Bacterial Infection Drugs Market - Global Outlook and Forecast 2023-2028

Report ID: 1370207 | Published Date: Jan 2025 | No. of Page: 69 | Base Year: 2024 | Rating: 4.2 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction to Research & Analysis Reports
    1.1 Gram-positive Bacterial Infection Drugs Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Gram-positive Bacterial Infection Drugs Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Gram-positive Bacterial Infection Drugs Overall Market Size
    2.1 Global Gram-positive Bacterial Infection Drugs Market Size: 2021 VS 2028
    2.2 Global Gram-positive Bacterial Infection Drugs Market Size, Prospects & Forecasts: 2017-2028
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Gram-positive Bacterial Infection Drugs Players in Global Market
    3.2 Top Global Gram-positive Bacterial Infection Drugs Companies Ranked by Revenue
    3.3 Global Gram-positive Bacterial Infection Drugs Revenue by Companies
    3.4 Top 3 and Top 5 Gram-positive Bacterial Infection Drugs Companies in Global Market, by Revenue in 2021
    3.5 Global Companies Gram-positive Bacterial Infection Drugs Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Gram-positive Bacterial Infection Drugs Players in Global Market
        3.6.1 List of Global Tier 1 Gram-positive Bacterial Infection Drugs Companies
        3.6.2 List of Global Tier 2 and Tier 3 Gram-positive Bacterial Infection Drugs Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 by Type - Global Gram-positive Bacterial Infection Drugs Market Size Markets, 2021 & 2028
        4.1.2 Antibiotic
        4.1.3 Antifungal
        4.1.4 Others
    4.2 By Type - Global Gram-positive Bacterial Infection Drugs Revenue & Forecasts
        4.2.1 By Type - Global Gram-positive Bacterial Infection Drugs Revenue, 2017-2022
        4.2.2 By Type - Global Gram-positive Bacterial Infection Drugs Revenue, 2023-2028
        4.2.3 By Type - Global Gram-positive Bacterial Infection Drugs Revenue Market Share, 2017-2028
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Gram-positive Bacterial Infection Drugs Market Size, 2021 & 2028
        5.1.2 Hospital Pharmacies
        5.1.3 Retail Pharmacies
        5.1.4 Online Pharmacies
    5.2 By Application - Global Gram-positive Bacterial Infection Drugs Revenue & Forecasts
        5.2.1 By Application - Global Gram-positive Bacterial Infection Drugs Revenue, 2017-2022
        5.2.2 By Application - Global Gram-positive Bacterial Infection Drugs Revenue, 2023-2028
        5.2.3 By Application - Global Gram-positive Bacterial Infection Drugs Revenue Market Share, 2017-2028
6 Sights by Region
    6.1 By Region - Global Gram-positive Bacterial Infection Drugs Market Size, 2021 & 2028
    6.2 By Region - Global Gram-positive Bacterial Infection Drugs Revenue & Forecasts
        6.2.1 By Region - Global Gram-positive Bacterial Infection Drugs Revenue, 2017-2022
        6.2.2 By Region - Global Gram-positive Bacterial Infection Drugs Revenue, 2023-2028
        6.2.3 By Region - Global Gram-positive Bacterial Infection Drugs Revenue Market Share, 2017-2028
    6.3 North America
        6.3.1 By Country - North America Gram-positive Bacterial Infection Drugs Revenue, 2017-2028
        6.3.2 US Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.3.3 Canada Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.3.4 Mexico Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
    6.4 Europe
        6.4.1 By Country - Europe Gram-positive Bacterial Infection Drugs Revenue, 2017-2028
        6.4.2 Germany Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.4.3 France Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.4.4 U.K. Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.4.5 Italy Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.4.6 Russia Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.4.7 Nordic Countries Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.4.8 Benelux Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
    6.5 Asia
        6.5.1 By Region - Asia Gram-positive Bacterial Infection Drugs Revenue, 2017-2028
        6.5.2 China Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.5.3 Japan Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.5.4 South Korea Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.5.5 Southeast Asia Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.5.6 India Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
    6.6 South America
        6.6.1 By Country - South America Gram-positive Bacterial Infection Drugs Revenue, 2017-2028
        6.6.2 Brazil Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.6.3 Argentina Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Gram-positive Bacterial Infection Drugs Revenue, 2017-2028
        6.7.2 Turkey Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.7.3 Israel Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.7.4 Saudi Arabia Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
        6.7.5 UAE Gram-positive Bacterial Infection Drugs Market Size, 2017-2028
7 Players Profiles
    7.1 Pfizer
        7.1.1 Pfizer Corporate Summary
        7.1.2 Pfizer Business Overview
        7.1.3 Pfizer Gram-positive Bacterial Infection Drugs Major Product Offerings
        7.1.4 Pfizer Gram-positive Bacterial Infection Drugs Revenue in Global Market (2017-2022)
        7.1.5 Pfizer Key News
    7.2 Sanofi
        7.2.1 Sanofi Corporate Summary
        7.2.2 Sanofi Business Overview
        7.2.3 Sanofi Gram-positive Bacterial Infection Drugs Major Product Offerings
        7.2.4 Sanofi Gram-positive Bacterial Infection Drugs Revenue in Global Market (2017-2022)
        7.2.5 Sanofi Key News
    7.3 GlaxoSmithKline
        7.3.1 GlaxoSmithKline Corporate Summary
        7.3.2 GlaxoSmithKline Business Overview
        7.3.3 GlaxoSmithKline Gram-positive Bacterial Infection Drugs Major Product Offerings
        7.3.4 GlaxoSmithKline Gram-positive Bacterial Infection Drugs Revenue in Global Market (2017-2022)
        7.3.5 GlaxoSmithKline Key News
    7.4 Bayer
        7.4.1 Bayer Corporate Summary
        7.4.2 Bayer Business Overview
        7.4.3 Bayer Gram-positive Bacterial Infection Drugs Major Product Offerings
        7.4.4 Bayer Gram-positive Bacterial Infection Drugs Revenue in Global Market (2017-2022)
        7.4.5 Bayer Key News
    7.5 Bristol-Myers Squibb
        7.5.1 Bristol-Myers Squibb Corporate Summary
        7.5.2 Bristol-Myers Squibb Business Overview
        7.5.3 Bristol-Myers Squibb Gram-positive Bacterial Infection Drugs Major Product Offerings
        7.5.4 Bristol-Myers Squibb Gram-positive Bacterial Infection Drugs Revenue in Global Market (2017-2022)
        7.5.5 Bristol-Myers Squibb Key News
    7.6 Novartis
        7.6.1 Novartis Corporate Summary
        7.6.2 Novartis Business Overview
        7.6.3 Novartis Gram-positive Bacterial Infection Drugs Major Product Offerings
        7.6.4 Novartis Gram-positive Bacterial Infection Drugs Revenue in Global Market (2017-2022)
        7.6.5 Novartis Key News
    7.7 Merck
        7.7.1 Merck Corporate Summary
        7.7.2 Merck Business Overview
        7.7.3 Merck Gram-positive Bacterial Infection Drugs Major Product Offerings
        7.7.4 Merck Gram-positive Bacterial Infection Drugs Revenue in Global Market (2017-2022)
        7.7.5 Merck Key News
    7.8 AstraZeneca
        7.8.1 AstraZeneca Corporate Summary
        7.8.2 AstraZeneca Business Overview
        7.8.3 AstraZeneca Gram-positive Bacterial Infection Drugs Major Product Offerings
        7.8.4 AstraZeneca Gram-positive Bacterial Infection Drugs Revenue in Global Market (2017-2022)
        7.8.5 AstraZeneca Key News
    7.9 Allergan
        7.9.1 Allergan Corporate Summary
        7.9.2 Allergan Business Overview
        7.9.3 Allergan Gram-positive Bacterial Infection Drugs Major Product Offerings
        7.9.4 Allergan Gram-positive Bacterial Infection Drugs Revenue in Global Market (2017-2022)
        7.9.5 Allergan Key News
    7.10 Theravance Biopharma
        7.10.1 Theravance Biopharma Corporate Summary
        7.10.2 Theravance Biopharma Business Overview
        7.10.3 Theravance Biopharma Gram-positive Bacterial Infection Drugs Major Product Offerings
        7.10.4 Theravance Biopharma Gram-positive Bacterial Infection Drugs Revenue in Global Market (2017-2022)
        7.10.5 Theravance Biopharma Key News
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

List of Tables
    Table 1. Gram-positive Bacterial Infection Drugs Market Opportunities & Trends in Global Market
    Table 2. Gram-positive Bacterial Infection Drugs Market Drivers in Global Market
    Table 3. Gram-positive Bacterial Infection Drugs Market Restraints in Global Market
    Table 4. Key Players of Gram-positive Bacterial Infection Drugs in Global Market
    Table 5. Top Gram-positive Bacterial Infection Drugs Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Gram-positive Bacterial Infection Drugs Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Gram-positive Bacterial Infection Drugs Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Gram-positive Bacterial Infection Drugs Product Type
    Table 9. List of Global Tier 1 Gram-positive Bacterial Infection Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Gram-positive Bacterial Infection Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Gram-positive Bacterial Infection Drugs Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Gram-positive Bacterial Infection Drugs Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Gram-positive Bacterial Infection Drugs Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Gram-positive Bacterial Infection Drugs Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2023-2028
    Table 30. Pfizer Corporate Summary
    Table 31. Pfizer Gram-positive Bacterial Infection Drugs Product Offerings
    Table 32. Pfizer Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), (2017-2022)
    Table 33. Sanofi Corporate Summary
    Table 34. Sanofi Gram-positive Bacterial Infection Drugs Product Offerings
    Table 35. Sanofi Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), (2017-2022)
    Table 36. GlaxoSmithKline Corporate Summary
    Table 37. GlaxoSmithKline Gram-positive Bacterial Infection Drugs Product Offerings
    Table 38. GlaxoSmithKline Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), (2017-2022)
    Table 39. Bayer Corporate Summary
    Table 40. Bayer Gram-positive Bacterial Infection Drugs Product Offerings
    Table 41. Bayer Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), (2017-2022)
    Table 42. Bristol-Myers Squibb Corporate Summary
    Table 43. Bristol-Myers Squibb Gram-positive Bacterial Infection Drugs Product Offerings
    Table 44. Bristol-Myers Squibb Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), (2017-2022)
    Table 45. Novartis Corporate Summary
    Table 46. Novartis Gram-positive Bacterial Infection Drugs Product Offerings
    Table 47. Novartis Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), (2017-2022)
    Table 48. Merck Corporate Summary
    Table 49. Merck Gram-positive Bacterial Infection Drugs Product Offerings
    Table 50. Merck Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), (2017-2022)
    Table 51. AstraZeneca Corporate Summary
    Table 52. AstraZeneca Gram-positive Bacterial Infection Drugs Product Offerings
    Table 53. AstraZeneca Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), (2017-2022)
    Table 54. Allergan Corporate Summary
    Table 55. Allergan Gram-positive Bacterial Infection Drugs Product Offerings
    Table 56. Allergan Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), (2017-2022)
    Table 57. Theravance Biopharma Corporate Summary
    Table 58. Theravance Biopharma Gram-positive Bacterial Infection Drugs Product Offerings
    Table 59. Theravance Biopharma Gram-positive Bacterial Infection Drugs Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Gram-positive Bacterial Infection Drugs Segment by Type in 2021
    Figure 2. Gram-positive Bacterial Infection Drugs Segment by Application in 2021
    Figure 3. Global Gram-positive Bacterial Infection Drugs Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Gram-positive Bacterial Infection Drugs Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Gram-positive Bacterial Infection Drugs Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Gram-positive Bacterial Infection Drugs Revenue in 2021
    Figure 8. By Type - Global Gram-positive Bacterial Infection Drugs Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Gram-positive Bacterial Infection Drugs Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Gram-positive Bacterial Infection Drugs Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Gram-positive Bacterial Infection Drugs Revenue Market Share, 2017-2028
    Figure 12. US Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Gram-positive Bacterial Infection Drugs Revenue Market Share, 2017-2028
    Figure 16. Germany Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 17. France Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Gram-positive Bacterial Infection Drugs Revenue Market Share, 2017-2028
    Figure 24. China Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 28. India Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Gram-positive Bacterial Infection Drugs Revenue Market Share, 2017-2028
    Figure 30. Brazil Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Gram-positive Bacterial Infection Drugs Revenue Market Share, 2017-2028
    Figure 33. Turkey Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Gram-positive Bacterial Infection Drugs Revenue, (US$, Mn), 2017-2028
    Figure 37. Pfizer Gram-positive Bacterial Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Sanofi Gram-positive Bacterial Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. GlaxoSmithKline Gram-positive Bacterial Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Bayer Gram-positive Bacterial Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Bristol-Myers Squibb Gram-positive Bacterial Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Novartis Gram-positive Bacterial Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Merck Gram-positive Bacterial Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. AstraZeneca Gram-positive Bacterial Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 45. Allergan Gram-positive Bacterial Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 46. Theravance Biopharma Gram-positive Bacterial Infection Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
69
Frequently Asked Questions
Gram-positive Bacterial Infection Drugs Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Gram-positive Bacterial Infection Drugs Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Gram-positive Bacterial Infection Drugs Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports